Skip to content

Comparison of sugammadex sodium versus neostigmine in the incidence of postoperative delirium in patients undergoing hip arthroplasty: a randomized controlled trial

Comparison of sugammadex sodium versus neostigmine in the incidence of postoperative delirium in patients undergoing hip arthroplasty: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104030
Enrollment
Unknown
Registered
2025-06-10
Start date
2024-10-09
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative delirium

Interventions

Sponsors

The First Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Meet the surgical indications and plan to undergo hip replacement surgery; 2. Age: 18-90 years old; 3. ASA level 1-3; 4. Clearly understand, voluntarily participate in the study, and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients who are known to be allergic to sugammadex sodium and neostigmine components; 2. There is abuse of psychotropic substances or alcohol; 3. Patients who cannot tolerate various adverse reactions of sugammadex sodium and neostigmine; 4. Merge severe cardiovascular and cerebrovascular diseases, respiratory system diseases, and severe immune system diseases, severe liver dysfunction, renal dysfunction; 5. A score of<15 on the Mini Mental State Examination (MMSE), combined with severe psychological disorders, cognitive impairment, any psychiatric disorders, skull or scalp injuries;   6. Visual or hearing impairment, communication difficulties; 7. Patients expected to enter the ICU 8. Other situations where the researcher deems it inappropriate to participate in this experiment.

Design outcomes

Primary

MeasureTime frame
The incidence of delirium within 3 days after surgery;Number of postoperative delirium episodes;

Secondary

MeasureTime frame
Pain score at 2 hours after surgery;Anxiety score at 1 day after surgery;Depression score at 1 day after surgery;From the end of anesthesia to the time of extubation;Delayed extubation;PACU time;The number of scores of MMSE 3 days after surgey;The time of TOFr recovered to 0.9;Subtypes of delirium;Time to first appearance of T2;TOFr at extubation;Incidence of SpO2<95% after surgery;Incidence of SpO2<90% after surgery;WBC count after surgery;NE count after surgery;ALT count after surgery;AST count after surgery;Albumin count after surgery;Glucose count after surgery;Scr count after surgery;Changes in heart rate before and after medication;Changes in blood pressure before and after medication;Time to first ventilation;Time to first defecation;Time to first off-bed activities;Length of hospital stay;Pain score at 24 hours after surgery;Pain score at 48 hours after surgery;Pain score at 72 hours after surgery;Anxiety score at 3 days after surgery;Depression score at 3 days after surgery;

Countries

China

Contacts

Public ContactYang Chun

The First Affiliated Hospital of Nanjing Medical University

chunyang@njmu.edu.cn+86 182 6006 2666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026